HALO · Insider Trading
Halozyme Therapeutics, Inc.
Every open-market purchase and sale reported by HALO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-08 | Bernadette Connaughton | Director | A | +3,796 | — |
| 2026-10-08 | Helen Torley | PRESIDENT AND CEO | MIXED | — | −$5.51M |
| 2026-10-02 | Matthew L. Posard | Director | Sell | −5,230 | −$567.66K |
| 2026-10-02 | James M Daly | Director | A | +1,169 | — |
| 2026-09-17 | Matthew L. Posard | Director | Sell | −18,996 | −$2.05M |
| 2026-09-11 | Helen Torley | PRESIDENT AND CEO | MIXED | — | −$5.33M |
| 2026-09-02 | Dannielle Appelhans | Director | A | +1,161 | — |
| 2026-08-19 | Helen Torley | PRESIDENT AND CEO | MIXED | — | −$5.17M |
| 2026-08-11 | Bernadette Connaughton | Director | Sell | −1,626 | −$167.15K |
| 2026-07-09 | Helen Torley | PRESIDENT AND CEO | MIXED | — | −$130.18K |
| 2026-07-02 | Bernadette Connaughton | Director | Sell | −1,625 | −$124.65K |
| 2026-07-02 | Darren Snellgrove | SVP, Chief Financial Officer | A | +168,986 deriv. | — |
| 2026-07-02 | David A Ramsay | EVP, PRESIDENT, DRUG DELIVERY | MIXED | +4,592 | −$423.28K |
| 2014-05-16 | — | — | — | — | — |
| 2014-05-15 | — | — | — | — | — |
| 2014-05-14 | — | — | — | — | — |
| 2014-05-14 | — | — | — | — | — |
| 2014-05-14 | — | — | — | — | — |
| 2014-05-14 | — | — | — | — | — |
| 2014-05-14 | — | — | — | — | — |
| 2014-05-14 | — | — | — | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Helen Torley | PRESIDENT AND CEO | 782,970 | $80.63M |
| Matthew L. Posard | Director | 53,709 | $5.53M |
| Bernadette Connaughton | Director | 42,294 | $4.36M |
| David A Ramsay | EVP, PRESIDENT, DRUG DELIVERY | 4,592 | $472.88K |
| James M Daly | Director | 1,169 | $120.38K |
| Dannielle Appelhans | Director | 1,161 | $119.56K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HALO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.